Becaplermin (PDGF-BB)

A recombinant human platelet-derived growth factor B-chain dimer used to promote WOUND HEALING by stimulating PHYSIOLOGIC ANGIOGENESIS.

Also Known As:

PDGF-BB; Platelet-Derived Growth Factor BB; Platelet-Derived Growth Factor BB, Recombinant; Recombinant Platelet-Derived Growth Factor BB; Regranex; rPDGF-BB; rhPDGF-BB; Platelet Derived Growth Factor BB; Platelet Derived Growth Factor BB, Recombinant; Recombinant Platelet Derived Growth Factor BB

Networked: 1342 relevant articles (74 outcomes, 216 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Cao, Yihai: 11 articles (01/2018 - 05/2003)
2.	Heldin, Carl-Henrik: 10 articles (01/2022 - 04/2004)
3.	Kim, Bokyung: 8 articles (07/2019 - 03/2009)
4.	Johnson, Mahlon D: 8 articles (12/2016 - 01/2002)
5.	Buch, Shilpa: 8 articles (01/2015 - 10/2008)
6.	Lynch, Samuel E: 8 articles (07/2013 - 06/2003)
7.	Yun, Yeo-Pyo: 8 articles (05/2013 - 01/2007)
8.	Lennartsson, Johan: 7 articles (01/2022 - 07/2010)
9.	Yao, Honghong: 7 articles (01/2015 - 10/2008)
10.	Kim, Tack-Joong: 7 articles (01/2011 - 01/2007)

Related Diseases

1.	Wounds and Injuries (Trauma) 03/17/2023 - "The PDGF-BB concentration of PB-PL was the highest and it decreased after the wound closed on day 3. Therefore, we concluded that PL from both sources can be a beneficial treatment for wound-healing, but PB-PL showed the most promising wound-healing properties in this study." 11/01/2011 - "Research to date has shown that NorLeu(3)-A(1-7) is highly effective in the closure of diabetic wounds and is superior to Regranex in animal studies. " 01/01/2008 - "Becaplermin plus good wound care may be cost effective in specific populations. " 03/01/2006 - "Our current study using commercially available Regranex failed to reproduce the previously reported finding that PDGF improved wound closure in healing impaired genetically diabetic mice." 11/01/2015 - "The rhPDGF-BB-loaded PLGA membranes considerably helped the diabetic wounds repairing. "
2.	Ulcer 12/01/2001 - "Recombinant human platelet derived growth factor-BB gel (PDGF gel) has been shown to be effective in the treatment of diabetic neuropathic ulcers. " 07/31/2016 - "The recombinant human PDGF-BB is safe and effective to stimulate the healing of chronic, full thickness and lower extremity diabetic neurotrophic ulcers. " 08/01/1998 - "Therefore, becaplermin gel appears to be a safe therapy for the treatment of lower extremity diabetic ulcers." 01/01/1995 - "Once-daily topical application of rhPDGF-BB is safe and effective in stimulating the healing of chronic, full-thickness, lower-extremity diabetic neurotrophic ulcers." 07/01/2000 - "Treatment of chronic ulcers in the lower extremities with topical becaplermin gel .01%: a multicenter open-label study."
3.	Diabetic Foot 06/01/2005 - "Although the sample size was not large enough to demonstrate that the incidence of healing in the OASIS group was statistically superior (P = .055), the study results showed that treatment with OASIS is as effective as Regranex in healing full-thickness diabetic foot ulcers by 12 weeks." 10/01/2002 - "Results of this analysis suggest that becaplermin may ultimately be more cost-effective for the treatment of chronic diabetic foot ulcers than other treatment modalities, despite its higher initial dollar cost. " 01/01/2001 - "Becaplermin may be a cost-effective treatment for neuropathic diabetic foot ulcers in a wide range of European settings. " 05/01/2015 - "Cost-effectiveness of becaplermin gel on wound healing of diabetic foot ulcers." 06/01/2010 - "Benefit-risk assessment of becaplermin in the treatment of diabetic foot ulcers."
4.	Fibrosis (Cirrhosis) 06/01/2009 - "lucidum inhibits PDGF-BB-activated HSC proliferation possibly through blocking PDGFbetaR phosphorylation, thereby indicating its efficacy for preventing and treating hepatic fibrosis." 03/01/2003 - "Taken together, the results of this study indicate that p38beta2 can function as a negative regulator of MMP-1 induced by PDGF-BB in vitro, suggesting that activation of p38beta2 might contribute to the pathogenesis of cutaneous fibrosis." 12/01/2023 - "The top combination to predict cirrhosis was HGF plus PDGF-BB. " 11/21/2023 - "We identified that HOXA11 over-expressed GC cells strongly propelled mesothelial fibrosis in vivo and in vitro, and HOXA11 regulated paracrine and autocrine of PDGF BB and TGF β1 in GC cells to propel mesothelial fibrosis. " 11/01/2019 - "Taken together, these results demonstrated that ASIV promoted cellular senescence and apoptosis by activating the NF-κB pathway to suppress PDGF-BB-induced HSC-T6 activation; with potential implications for the treatment of hepatic fibrosis."
5.	Gingival Recession 03/01/2014 - "The combination of rhPDGF-BB and β-TCP represented a therapeutic combination that was effective in treating multiple gingival recession defects. " 09/08/2023 - "rhPDGF-BB has been extensively applied for periodontal regenerative procedures and for the treatment of gingival recessions, showing consistent and positive outcomes. " 12/01/2022 - "Overall, rhPDGF-BB exhibited the largest effect size for most parameters, including clinical attachment level gain, pocket depth reduction, less gingival recession and radiographic linear bone gain. " 03/01/2020 - "Treatment of Multiple Mandibular Gingival Recession Defects Using MCAT Technique and SCTG With and Without rhPDGF-BB: A Randomized Controlled Clinical Trial." 01/01/2017 - "In the case of patients suffering only from gingival recession, however, the application of rhPDGF-BB produces no significant regenerative advantage. "

Related Drugs and Biologics

1.	Becaplermin (PDGF-BB)
2.	Platelet-Derived Growth Factor
3.	Intercellular Signaling Peptides and Proteins (Growth Factors)
4.	Collagen
5.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
6.	Oxygen (Dioxygen)
7.	beta-tricalcium phosphate
8.	Imatinib Mesylate (Gleevec)
9.	Peptides (Polypeptides)
10.	Proteins (Proteins, Gene)

Related Therapies and Procedures

1.	Therapeutics
2.	Aftercare (After-Treatment)
3.	Surgical Amputation (Amputations)
4.	Injections
5.	Topical Administration